Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2011-09-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 9
- Registration Number
- NCT00791323
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Choroidal NeovascularizationAge-Related Maculopathy
- Interventions
- Biological: ranibizumab
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 44
- Registration Number
- NCT00775411
Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms
Phase 4
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 50
- Registration Number
- NCT00761202
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
Phase 4
Completed
- Conditions
- Blepharospasm
- Interventions
- Biological: Botulinum Toxin Type A 900kDaBiological: Botulinum Toxin Type A 150kDa
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 65
- Registration Number
- NCT00761592
Efficacy and Acceptability of Two Lubricant Eye Drops
Phase 4
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: Lubricant Eye Drops (Optiveā¢)Drug: Lubricating Eye Drops (blinkĀ® Tears)
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 51
- Registration Number
- NCT00756678
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
Phase 4
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 204
- Registration Number
- NCT00735449
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
Completed
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2012-01-12
- Lead Sponsor
- Allergan
- Target Recruit Count
- 781
- Registration Number
- NCT00717418
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1099
- Registration Number
- NCT00716742
A Study of 2 Doses of MAP0010 in Asthmatic Children
Phase 3
Terminated
- Conditions
- Asthma
- Interventions
- Drug: 0.135mg MAP0010Drug: 0.25mg MAP0010
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 192
- Registration Number
- NCT00697697
Study of MAP0010 in Asthmatic Children and Adolescents
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: MAP0010 low doseDrug: MAP0010 high dose
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 208
- Registration Number
- NCT00697801
Ā© Copyright 2025. All Rights Reserved by MedPath